Kayne Anderson Rudnick Investment Management
MCRB icon

Kayne Anderson Rudnick Investment Management’s Seres Therapeutics MCRB Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12
Closed -$2K – 652
2022
Q1 		$2K Buy
+12
New +$1.85K ﹤0.01% 598

Other funds holding MCRB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's MCRB Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Seres Therapeutics (MCRB) in Q2 2022, closing a stake of 12 shares — an estimated $2K sold.

Kayne Anderson Rudnick Investment Management first reported a position in MCRB in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Seres Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 12 Seres Therapeutics shares in Q2 2022, an estimated $2K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Seres Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Seres Therapeutics position peaked at $2K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.